690 Stock Overview
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China.
Uni-Bio Science Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.08|
|52 Week High||HK$0.11|
|52 Week Low||HK$0.054|
|1 Month Change||-4.76%|
|3 Month Change||11.11%|
|1 Year Change||-20.00%|
|3 Year Change||-54.29%|
|5 Year Change||-59.60%|
|Change since IPO||-83.53%|
Recent News & Updates
Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)
How far off is Uni-Bio Science Group Limited ( HKG:690 ) from its intrinsic value? Using the most recent financial...
|690||HK Biotechs||HK Market|
Return vs Industry: 690 exceeded the Hong Kong Biotechs industry which returned -52.7% over the past year.
Return vs Market: 690 exceeded the Hong Kong Market which returned -21.6% over the past year.
|690 Average Weekly Movement||10.1%|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 690 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 690's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes.
Uni-Bio Science Group Fundamentals Summary
|690 fundamental statistics|
Is 690 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|690 income statement (TTM)|
|Cost of Revenue||HK$76.40m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0031|
|Net Profit Margin||-5.54%|
How did 690 perform over the long term?See historical performance and comparison
Is 690 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 690?
Other financial metrics that can be useful for relative valuation.
|What is 690's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 690's PS Ratio compare to its peers?
|690 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
8158 China Regenerative Medicine International
8247 Biosino Bio-Technology and Science Incorporation
1228 CANbridge Pharmaceuticals
1875 TOT BIOPHARM International
690 Uni-Bio Science Group
Price-To-Sales vs Peers: 690 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (12x).
Price to Earnings Ratio vs Industry
How does 690's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 690 is good value based on its Price-To-Sales Ratio (1.4x) compared to the Hong Kong Biotechs industry average (26.7x)
Price to Sales Ratio vs Fair Ratio
What is 690's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.4x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 690's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 690's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 690's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Uni-Bio Science Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uni-Bio Science Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Uni-Bio Science Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Uni-Bio Science Group competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Uni-Bio Science Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 690 is currently unprofitable.
Growing Profit Margin: 690 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 690 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.4% per year.
Accelerating Growth: Unable to compare 690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.2%).
Return on Equity
High ROE: 690 has a negative Return on Equity (-11.24%), as it is currently unprofitable.
Discover strong past performing companies
How is Uni-Bio Science Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 690's short term assets (HK$201.7M) exceed its short term liabilities (HK$92.3M).
Long Term Liabilities: 690's short term assets (HK$201.7M) exceed its long term liabilities (HK$985.0K).
Debt to Equity History and Analysis
Debt Level: 690 is debt free.
Reducing Debt: 690 has no debt compared to 5 years ago when its debt to equity ratio was 2.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 690 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 690 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.6% per year.
Discover healthy companies
What is Uni-Bio Science Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 690's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 690's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 690's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 690's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 690 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Frank Zhao (57 yo)
Mr. Zhi GangZhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer at...
CEO Compensation Analysis
Compensation vs Market: Frank's total compensation ($USD199.65K) is about average for companies of similar size in the Hong Kong market ($USD246.27K).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
Experienced Management: 690's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: 690's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Uni-Bio Science Group Limited's employee growth, exchange listings and data sources
- Name: Uni-Bio Science Group Limited
- Ticker: 690
- Exchange: SEHK
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$509.181m
- Shares outstanding: 6.36b
- Website: https://www.uni-bioscience.com
Number of Employees
- Uni-Bio Science Group Limited
- No. 20 Science Park East Avenue
- Unit 502
- Sha Tin
- New Territories
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/13 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.